![rapt training rapt training](https://i.pinimg.com/736x/f3/69/4c/f3694c8b278db71946686971d45312b3.jpg)
Earlier in his career, he was an investment banker at Lehman Brothers and SG Cowen, leading financing and merger and acquisition transactions focused in the healthcare, biotechnology, and pharmaceutical sectors. Previously, he served as Chief Financial Officer and Vice President of Finance and Administration of StemCells, Inc., a public biotechnology company developing stem cell therapeutics for central nervous system disorders, where he was responsible for raising over $200 million in financing. At Cellerant, he was responsible for accounting and financial management, and played a key role in corporate strategy. Most recently, he served as Chief Financial Officer of Cellerant Therapeutics, Inc., a private clinical-stage company developing cell and antibody-based immunotherapies for blood cancers and related disorders. He brings more than 30 years of executive management and corporate finance experience. Rodney joined RAPT Therapeutics in December 2019.
![rapt training rapt training](https://www.childsafety.co.uk/images_CMS/page/7/1427807798_7_Image_BannerImage.jpg)
Bill completed his internship and residency in Internal Medicine at the University of California, San Francisco, and received his training in Medical Oncology at the University of Washington and Fred Hutchinson Cancer Research Center, where he studied adoptive immunotherapy methods to treat leukemia. in Microbiology and Immunology from the Stanford University School of Medicine, where he studied cellular immunology in the laboratory of Mark Davis, Ph.D. in Molecular Biology from Princeton University and both his M.D.
![rapt training rapt training](https://childwelfare.iu.edu/images/RAPT-Diabetes-Lunch-and-Learn.jpg)
Prior to Igenica, Bill served as a Senior Medical Director in the Exploratory Clinical Development (BioOncology) group at Genentech, where for seven years he led the development of multiple small molecule, antibody, and antibody-drug conjugate programs from IND filing to Phase III, including clinical development of Gazyva ® (obinutuzumab), Venclexta™ (venetoclax) and Polivy™ (polatuzumab vedotin-piiq).īill received his A.B. He joined RAPT Therapeutics after serving as the Vice President of Clinical Development at Igenica Biotherapeutics, where he led the clinical development of antibody-based therapeutics. xīill joined RAPT Therapeutics as Chief Medical Officer in 2015, bringing with him extensive experience both in clinical immunotherapy and in the translational and clinical development of novel therapeutics to treat cancer. He has co-authored 40 scientific papers and is a named inventor on seven issued patents and several pending applications. He was a post-doctoral fellow at the Stanford School of Medicine in the Department of Pathology. from the University of Kiel (graduate work performed at Stanford University). in Microbiology from the University of Kiel, and he earned his Ph.D. Prior to Cerus, he served as a scientist at Aventis in the immunotherapy and anti-angiogenesis group, developing novel therapies against cancer.ĭirk holds an M.S. Prior to Aduro, Dirk held positions of increasing responsibility within the immunology department of Cerus Corporation, most recently serving as Director of Immunology. He joined RAPT from Aduro Biotech, where he served as Executive Vice President of Research and Development. We are also pursuing a range of other targets, including HPK1, that are in earlier stages of discovery and development.ĭirk joined RAPT Therapeutics in January 2018, bringing over 20 years of experience through all stages of discovery, translational and clinical development, as well as a deep knowledge of immunology and the tumor microenvironment. Our lead oncology drug candidate, FLX475, is in development for a range of tumors. In a randomized, placebo-controlled Phase 1b study in patients with atopic dermatitis, our lead inflammation drug candidate, RPT193, demonstrated clinically meaningful improvement in several exploratory endpoints. Since our founding, we have discovered and advanced to clinical development two drug candidates, each targeting CCR4. Utilizing our proprietary drug discovery and development engine, we develop highly selective small molecules that are designed to modulate the critical immune responses underlying these diseases. RAPT Therapeutics is a clinical stage immunology-based biopharmaceutical company focused on discovering, developing and commercializing oral small molecule therapies for patients with significant unmet needs in oncology and inflammatory diseases. TO CONQUER CANCER AND INFLAMMATORY DISEASE
![rapt training rapt training](https://pbs.twimg.com/profile_images/1103048269960265728/AU1e2sQc_400x400.png)
COMMITTED TO DISCOVERING BEST-IN-CLASS ORAL THERAPIES